Agios Prescription drugs, Inc. (AGIO) Discusses New Information and Strategic Enlargement in Uncommon Hematology at EHA Investor Occasion Transcript

FollowPlay Earnings CallPlay Earnings Call

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event June 13, 2026 9:00 AM EDT

Company Participants

Morgan Sanford – Vice President of Investor Relations
Brian Goff – CEO & Director
Sarah Gheuens – Chief Medical Officer and Head of Research & Development
Ahmar Zaidi
Tsveta Milanova – Chief Commercial Officer

Conference Call Participants

Alan Anderson
Kenneth Ataga
Andrew Berens – Leerink Partners LLC, Research Division
Eric Schmidt – Cantor Fitzgerald & Co., Research Division
Samantha Semenkow – Citigroup Inc., Research Division
Anish Nikhanj – Truist Securities, Inc., Research Division
Emily Bodnar – H.C. Wainwright & Co, LLC, Research Division
Lydia Erdman – Goldman Sachs Group, Inc., Research Division
Tessa Romero – JPMorgan Chase & Co, Research Division
Luca Issi – RBC Capital Markets, Research Division

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Agios Pharmaceuticals European Hematology Association 2026 Investor Webcast and Conference Call.

(Operator Instructions) Please be advised that today’s call is being recorded. I would now like to hand it over to our first speaker, Morgan Sanford, Head of Investor Relations at Agios. Please go ahead.

Morgan Sanford
Vice President of Investor Relations

Thank you, operator. Good morning and good afternoon, everyone, and thank you for joining us. We’re pleased to host today’s webcast in conjunction with the 2026 EHA Congress, where we are presenting a broad set of data across our portfolio. You can access the slides for today’s presentation on the Investors section of our website.

Please note that we will be making forward-looking statements during this presentation. Actual results may differ materially due to risks and uncertainties described in our SEC filings.

Joining me today are Brian Goff, Chief Executive Officer; Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D; and Tsveta Milanova, Chief Commercial Officer. We will also be joined for Q&A by our participating key opinion

Source link